For the quarter ended September 2025, Amphastar Pharmaceuticals (AMPH) reported revenue of $191.84 million, up 0.3% over the same period last year. EPS came in at $0.93, compared to $0.96 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $184.53 million, representing a surprise of +3.96%. The company delivered an EPS surprise of +20.78%, with the consensus EPS estimate being $0.77.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Amphastar performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net revenues- Primatene MIST: $28.81 million versus the two-analyst average estimate of $25.39 million. The reported number represents a year-over-year change of +10.6%.
- Net revenues- Glucagon: $13.56 million versus $17.98 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -49.4% change.
- Net revenues- Lidocaine: $12.93 million versus the two-analyst average estimate of $15.24 million. The reported number represents a year-over-year change of -18.6%.
- Net revenues- Epinephrine: $18.79 million versus the two-analyst average estimate of $15.64 million. The reported number represents a year-over-year change of -12%.
View all Key Company Metrics for Amphastar here>>>
Shares of Amphastar have returned -2.6% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amphastar Pharmaceuticals, Inc. (AMPH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
